Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations
Communiqués de presse de la société MERCK & CO., INC.
10/23MERCK : Donates $500,000 to Support River Blindness and Lymphatic Filariasis Eli..
AQ
10/23MERCK : PHIL, MERCK Partner to Reach Girls With HPV Vaccine
AQ
10/22MERCK : Donates $500,000 to Support River Blindness and Lymphatic Filariasis Eli..
BU
10/21SANOFI : Merck and Sanofi to Present Three New Studies Highlighting Combination ..
AQ
10/21MERCK : Announces Positive Topline Results from Two Additional Phase 3 Adult Stu..
AQ
10/21MERCK : to Present New Data from its Extensive Infectious Diseases and Vaccines ..
BU
10/20MERCK : and Sanofi to Present Three New Studies Highlighting Combination Pediatr..
PU
10/20MERCK : Announces Positive Topline Results from Two Additional Phase 3 Adult Stu..
BU
10/16MERCK : Presents Three-Year Survival Data for KEYTRUDA® (pembrolizumab) in Combi..
BU
10/16MERCK : FDA Approves Expanded Indication for Merck's KEYTRUDA in Adult Patients ..
AQ
10/15MERCK : Issues 2019, 2020 Corporate Responsibility Report
AQ
10/15MERCK : Health Canada Approves KEYTRUDA® (pembrolizumab) as First-line Treatment..
AQ
10/15MERCK : FDA Approves Expanded Indication for Merck's KEYTRUDA® (pembrolizumab) i..
BU
10/14MERCK : Announces Plans to Construct New Facility in the United States to Expand..
PU
10/14MERCK : Issues 2019/2020 Corporate Responsibility Report
BU
10/09MERCK : Intec Pharma Announces New Research Collaboration Agreement with MSD
AQ
10/09MODERNA : Announces Updates on Respiratory Syncytial Virus Vaccine Program
AQ
10/08MERCK : Announces Week 96 Data from Phase 2b Study Evaluating Islatravir in Comb..
BU
10/05MERCK : Announces Retirement of Dr. Roger M. Perlmutter, Dr. Dean Y. Li Appointe..
AQ
10/02MERCK : to Hold Third-Quarter 2020 Sales and Earnings Conference Call on October..
AQ
10/02MERCK : to Present New Data from the Company's Diverse HIV Portfolio and Pipelin..
AQ
10/02MERCK : Announces Retirement of Dr. Roger M. Perlmutter; Dr. Dean Y. Li Appointe..
BU
10/01MERCK : to Present New Data from the Company's Diverse HIV Portfolio and Pipelin..
BU
10/01MERCK : to Hold Third-Quarter 2020 Sales and Earnings Conference Call on October..
BU
09/30CELYAD : Oncology Announces Clinical Trial Collaboration to Evaluate CYAD-101 wi..
AQ
09/29MERCK : Animal Health Supports Rabies Elimination by 2030 on World Rabies Day
AQ
09/29MERCK : Enters into Voluntary Licensing Agreements for Doravirine to Expand Pati..
PU
09/28MERCK : Animal Health Supports Rabies Elimination by 2030 on World Rabies Day
BU
09/24MERCK : 4D pharma plc - Directorate Change
AQ
09/24MERCK : NEXPLANON® Contraceptive Arm Implant Now Available for Use in Canada
AQ
09/23MERCK : 4D pharma makes strategic appointment of independent Non-Executive Direc..
AQ
09/22MERCK : Merk Oncology Overview ESMO 2020 Presentation
PU
09/21MERCK : KEYTRUDA® (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27%..
BU
09/21MERCK : And eisai present first-time data from two studies evaluating keytruda p..
AQ
09/21MERCK : First-Line Treatment With Merck's KEYTRUDA® (pembrolizumab) Doubled Five..
BU
09/21MERCK : LYNPARZA® (olaparib) Receives Positive Opinion from EU CHMP for Treatmen..
BU
09/21MERCK : LYNPARZA® (olaparib) Recommended for Approval in EU by CHMP as First-Lin..
BU
09/20MERCK : LYNPARZA Reduced Risk of Death by 31% vs. Enzalutamide or Abiraterone fo..
BU
09/20MERCK : Presents Promising New Data for Three Investigational Medicines From Div..
BU
09/20MERCK : and Eisai Present First-Time Data From Two Studies Evaluating KEYTRUDA® ..
BU
09/19MERCK : KEYTRUDA® (pembrolizumab) Reduced the Risk of Distant Metastasis or Deat..
BU
09/18MERCK : LYNPARZA® (olaparib) Improved Median Progression-Free Survival to Over F..
BU
09/17MERCK : to Hold Investor Briefing Following ESMO Virtual Congress 2020
AQ
09/16MERCK : to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Confe..
AQ
09/16MERCK : to Hold Investor Briefing Following ESMO Virtual Congress 2020
BU
09/15SEATTLE GENETICS : and Merck Announce Two Strategic Oncology Collaborations
AQ
09/15MERCK : BRENZYS® (etanercept injection) now indicated for the Treatment of Plaqu..
AQ
09/15MERCK : to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Confe..
BU
09/15MERCK : HHS Can't Force Disclosure Of Drug Prices In Ads With "Blunderbuss" Rule
AQ
09/14EISAI : To present abstracts on oncology products and pipeline at esmo virtual c..
AQ
09/14MERCK : Seattle Genetics and Merck Announce Two Strategic Oncology Collaboration..
BU
09/10MERCK : Announces Positive Topline Results from Two Phase 3 Adult Studies Evalua..
AQ
09/10MERCK : Intensity Therapeutics Doses First Patients with Combination of INT230-6..
AQ
09/10MERCK : to Present at the Morgan Stanley 18th Annual Virtual Global Healthcare C..
BU
09/09MERCK : Gefapixant Significantly Decreased Cough Frequency Compared to Placebo a..
AQ
09/09Biopharma Leaders Unite To Stand With Science
AQ
09/09AstraZeneca - Biopharma Leaders Unite to Stand With Science
AQ
09/09Biopharma Leaders Unite To Stand With Science; Nine CEOs sign historic pledge..
AQ
09/09MERCK : Announces Positive Topline Results from Two Phase 3 Adult Studies Evalua..
BU
09/08MERCK : Gefapixant (45 mg Twice Daily) Significantly Decreased Cough Frequency C..
BU
09/04MERCK : to Present at the Citi 15th Annual BioPharma Virtual Conference
BU
09/03MERCK : New Scientific Data at the ESMO Virtual Congress 2020 Reflect Merck's Co..
AQ
09/02MERCK : New Scientific Data at the ESMO Virtual Congress 2020 Reflect Merck's Co..
BU
09/01TRIRX PHARMACEUTICAL SERVICES : acquires MSD Animal Health manufacturing site lo..
PR
08/31MERCK : Bayer submits vericiguat for marketing authorization in China for the tr..
AQ
08/27MERCK : 4D pharma plc - Comprehensive clinical benefit data from Part A of combi..
AQ
08/26MERCK : 4D pharma announces comprehensive clinical benefit data from Part A of c..
AQ
08/26IMMUTEP : New Data From Immutep's Efti To Be Presented At ESMO
AQ
08/25MERCK : KEYTRUDA Receives Two New Approvals in Japan
AQ
08/24MERCK : KEYTRUDA® (pembrolizumab) Receives Two New Approvals in Japan
BU
08/21SELLAS LIFE SCIENCES : Offers Strong Quarterly Update; Trials and Balance Sheet ..
AQ
08/20MERCK : KEYTRUDA in Combination with Chemotherapy Significantly Improved Overall..
AQ
08/20TARGOVAX ASA : second quarter and first half 2020 results
AQ
08/19MERCK : KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy Significantly..
BU
08/19MERCK : Ivermectin Triple Therapy Protocol for COVID-19 Released to Australian G..
AQ
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on MERCK & CO., INC.